Gov. Hohcul announced part of Saint Rose campus will be turned into a workforce development hub as part of the ON RAMP initiative ...

PORTLAND, Ore. (KOIN) — Bob’s Red Mill, the Milwaukie company founded on love of healthy foods and milling whole grains, announced the upcoming closure of their retail store and cafe Saturday ...

MILWAUKIE Ore. (KPTV) - Bob’s Red Mill will close its Whole Grain Store and restaurant in Milwaukie this month, the company announced Saturday. The store and restaurant have been open for 22 years.

PORTLAND, Ore. (KATU) — Bob's Red Mill has announced the closure of its Whole Grain Store and Café, citing financial losses as the reason behind the decision. "Despite everyone’s hard work ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

The decision affects 44 workers at the iconic company's Milwaukie location. Bob’s Red Mill is closing its Milwaukie retail outlet and café. The decision affects 44 employees at the 22-year-old ...

Red tide is caused by an microscopic algae called karenia brevis. Health alerts for red tide have been issued for several areas in Southwest Florida. Red tides can last for days, weeks or months.

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating ...

Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD). The ...

TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: TD Cowen 45th Annual Health Care Conference at ...

Regeneron Pharmaceuticals, Inc. and CytomX Therapeutics, Inc. have announced a strategic research collaboration within the field of conditionally activated bispecific therapeutics for the ...

Regeneron has signed a collaboration deal potentially worth $1 billion with RNAi experts Alnylam Pharmaceuticals, to develop and commercialise drugs targeting eye, central nervous system (CNS ...